4/15
08:00 am
amrn
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Low
Report
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
4/8
08:00 am
amrn
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
Medium
Report
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
4/7
07:48 am
amrn
Amarin (AMRN) was upgraded by Zacks Research from "hold" to "strong-buy".
Low
Report
Amarin (AMRN) was upgraded by Zacks Research from "hold" to "strong-buy".
3/18
08:30 am
amrn
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
Medium
Report
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
3/16
08:15 am
amrn
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientif
Low
Report
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientif
3/6
06:54 am
amrn
Amarin (AMRN) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Amarin (AMRN) was upgraded by Zacks Research from "strong sell" to "hold".
3/2
08:00 am
amrn
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
Low
Report
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
2/25
02:36 pm
amrn
Amarin Corp PLC (AMRN) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines with ... [Yahoo! Finance]
Medium
Report
Amarin Corp PLC (AMRN) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines with ... [Yahoo! Finance]
2/25
11:27 am
amrn
Amarin Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Amarin Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
10:51 am
amrn
Amarin (AMRN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Amarin (AMRN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
07:18 am
amrn
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/25
07:00 am
amrn
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
2/23
08:00 am
amrn
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Low
Report
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
2/11
08:00 am
amrn
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Low
Report
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
1/29
07:41 am
amrn
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.